EQS-News: Newron Pharmaceuticals S.p.A.
/ Key word(s): Financing
Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement EIB agrees to extend repayment dates of tranches one to three of its loan to the Company until end of 2025 and into 2026, after potentially significant pipeline milestones Amended agreement envisages EIB will now receive certain performance-based remuneration Milan, Italy, March 15, 2024, 07:00 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), today reports agreement with the European Investment Bank (EIB) on an amendment to certain terms of its 2018 financing agreement. Under the amendment, repayment of tranches one to three (out of a total of five) of the financing agreement with due dates from June 2024 to April 2025 will be shifted substantially, with tranche one now scheduled for November 25, 2025, tranche two for April 2026 and tranche three for June 2026. The due dates for tranches four and five will stay unchanged. On the amended tranches, Newron will start paying the agreed interest rates. The EIB will now qualify for certain performance-based remuneration. The agreement contains further terms and conditions. Details of the 2018 loan agreement can be found in Newron’s 2022 Annual Report which is posted on its website. Roberto Galli, Newron’s CFO, commented: “We appreciate the support of the EIB in helping us align our contractual obligations under our loan agreement with them to the potential timing of certain upcoming significant value inflection points presented by our pipeline of innovative therapies. Here, we remain extremely excited by the emerging profile of our lead drug candidate evenamide, which is in final stages of clinical development for the potential treatment of patients suffering from schizophrenia, particularly those who are resistant to currently approved drugs and where clinical data to date has been exceptional.” About Newron Pharmaceuticals For more information, please contact: Newron UK/Europe Switzerland Germany/Europe USA Important Notices
15.03.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
1859333 15.03.2024 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.